AI주식인사이트AI Stock Insight
C

오스코텍

039200KOSDAQ의약품 제조업

52.7 / 100

Reference Date: 2026-07-24

Financial Score22.0 / 40
News Sentiment17.7 / 25
Momentum3.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Plunged 17.4% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Oskotech is a research-focused biopharmaceutical company specializing in new drug development, functional materials, and dental bone grafts. It is currently conducting clinical trials for two synthetic drug candidates and holds a targeted anti-cancer drug approved by the US FDA. Major revenue streams come from technology transfer milestones and royalty income.

Number of Employees

57people

Average Salary

61.6M KRW

Score Calculation Basis

Detailed Financial Score

PER
22.81Industry Average 11.230.0Point

2.0x industry avg (risky)

PBR
6.39Industry Average 0.810.0Point

7.9x industry avg (risky)

ROE
34.08Industry Average 4.017.0Point

8.5x industry avg (excellent)

Debt Ratio
2.16Industry Average 12.438.0Point

Half of industry avg (excellent)

Trend 2023~20257.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲390.2% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲1048.3% (2-year basis)

ROE Trend
1.0 / 4

Avg ROE 2.1% (improving, 3yr)

Detailed News Sentiment

17 totalPositive 10Neutral 6Negative 1Average Sentiment Score 70.9

Detailed Momentum

52-week position1.0Point

Near 52w low (9%, downtrend)

Current 31,200Won52-week high 62,00052-week low 28,000
1-month return0.0Point

1m -17.35% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-07-23
  • Neutral기업설명회(IR)개최2026-07-03